SCHEMBL2391844

SCHEMBL2391844

Fc1ccc(-c2ccc[c]c2-c2cccs2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.43
PTGER2 P43116 1/20 0.43
RAB9A P51151 7/20 0.42
NPC1 O15118 6/20 0.42
KDM4E B2RXH2 5/20 0.42
ATM Q13315 1/20 0.42
ALDH1A1 P00352 4/20 0.41
HPGD P15428 4/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391838 0.88 RAB9A (0.42) MAPTPTGER2RAB9ANPC1KDM4E
SCHEMBL3176511 0.81 LTA4H (0.40) MAPTRAB9ANPC1KDM4EATM
SCHEMBL5014600 0.79 PTGS2 (0.39) MAPTRAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL10848415 0.76 MAPT (0.35) MAPTRAB9ANPC1KDM4EATM
SCHEMBL9559722 0.75 PTGS2 (0.40) MAPTALDH1A1HPGDMAPK14
SCHEMBL9559797 0.73 PTGS2 (0.39) MAPTMEN1KMT2AMAPK14POLB
SCHEMBL154088 0.73 MAPT (0.61) MAPTPTGER2RAB9ANPC1KDM4E
SCHEMBL2393866 0.73 ALDH1A1 (0.48) MAPTRAB9ANPC1KDM4EALDH1A1
SCHEMBL6661757 0.73 LTA4H (0.39) MAPTRAB9ANPC1KDM4EATM
SCHEMBL1990593 0.72 MAPT (0.59) MAPTPTGER2RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026263-B2 Methods for inhibiting neoproliferative changes in blood vessel walls THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-09-27 US disclosed
US-20090048270-A1 Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-02-19 US disclosed
US-20070293554-A1 Non-peptide inhibition of T-lymphocyte activation and therapies related thereto THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2007-12-20 US disclosed
US-7235577-B1 Non-peptide inhibition of T-lymphocyte activation and therapies related thereto THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-06-26 US disclosed
US-6803375-B1 IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048270-A1 Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls PGF, VEGFA, MKI67 MAPT 4284/4885PTGER2 469/4885RAB9A 1955/4885
US-20070293554-A1 Non-peptide inhibition of T-lymphocyte activation and therapies related thereto NFATC1, ORAI1, KCNMA1 MAPT 4757/4885PTGER2 1447/4885RAB9A 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.